Nex Eye
Nex Eye is a start-up that develops first-in-class antibodies targeting refractory factors of immuno-oncology drugs.
Nex Eye is active in the medical, oncology, pharmaceutical space based in Asia-Pacific (APAC), founded in 2021.
Within the medical, oncology, pharmaceutical space, the company focuses on its core offering rather than a broad product line.
Asia-Pacific (APAC) is where the company is located.
Directory data places it at the Series_A stage.
Public records show total funding of about $26B.
| Sector | Medical, Oncology, Pharmaceutical |
|---|---|
| Headquarters | Asia-Pacific (APAC) |
| Founded | 2021 |
| Stage | series_a |
| Total funding | $26,000,000,000 |
Website: www.nex-i.co.kr
Contact details and direct channels are available to signed-in members.
Create a free account
Create a free account